A citation-based method for searching scientific literature




Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
Times Cited: 1574




List of shared articles



Times cited

A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe.
S Seidu, X Cos, S Brunton, S B Harris, S P O Jansson, M Mata-Cases, A M J Neijens, P Topsever, K Khunti. Prim Care Diabetes 2021
11

Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.
Adriana Marton, Tatsuroh Kaneko, Jean-Paul Kovalik, Atsutaka Yasui, Akira Nishiyama, Kento Kitada, Jens Titze. Nat Rev Nephrol 2021
17

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Austin G Stack, David Han, Ronald Goldwater, Susanne Johansson, Nalina Dronamraju, Jan Oscarsson, Eva Johnsson, Joanna Parkinson, Fredrik Erlandsson. J Clin Endocrinol Metab 2021
4

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
3

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
11

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
12

Latin American Expert Consensus for Comprehensive Management of Type 2 Diabetes from a Metabolic-Cardio-Renal Perspective for the Primary Care Physician.
Roopa Mehta, Daniel Pichel, Chih Hao Chen-Ku, Pablo Raffaele, Antonio Méndez Durán, Francisco Padilla, Jose Javier Arango Alvarez, José Esteban Costa Gil, Juan Esteban Gómez Mesa, Mariano Giorgi,[...]. Diabetes Ther 2021
0

Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease.
Sho Kinguchi, Hiromichi Wakui, Yuzuru Ito, Yoshinobu Kondo, Kengo Azushima, Uru Osada, Tadashi Yamakawa, Tamio Iwamoto, Jun Yutoh, Toshihiro Misumi,[...]. Sci Rep 2021
0

[Kidney as pacemaker for cardiovascular aging].
Christoph Wanner, Jan Galle, Kai Lopau. Dtsch Med Wochenschr 2021
0

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
David Z I Cherney, Bernard Charbonnel, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Annpey Pong,[...]. Diabetologia 2021
13

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
9

Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
Jessica A Starr, Nathan A Pinner, Katelin M Lisenby, Alyssa Osmonson. Pharmacotherapy 2021
1

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin,[...]. Eur J Heart Fail 2021
1

Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease.
Masanori Wakisaka, Kuniyuki Nakamura, Toshiaki Nakano, Takanari Kitazono. J Endocr Soc 2021
0

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
Ofri Mosenzon, Stephen D Wiviott, Hiddo J L Heerspink, Jamie P Dwyer, Avivit Cahn, Erica L Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A Murphy,[...]. Diabetes Care 2021
1


The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
Jiang Liu, Jiang Tian, Komal Sodhi, Joseph I Shapiro. J Membr Biol 2021
1


2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
921

Renal effects of SGLT2 inhibitors: an update.
Josselin Nespoux, Volker Vallon. Curr Opin Nephrol Hypertens 2020
13

Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition.
Nitin A Das, Andrea J Carpenter, Anthony Belenchia, Annayya R Aroor, Makoto Noda, Ulrich Siebenlist, Bysani Chandrasekar, Vincent G DeMarco. Cell Signal 2020
21


Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
Takahiro Masuda, Shigeaki Muto, Keiko Fukuda, Minami Watanabe, Ken Ohara, Hermann Koepsell, Volker Vallon, Daisuke Nagata. Physiol Rep 2020
19

Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan.
Kota Yano, Yuya Seko, Aya Takahashi, Shinya Okishio, Seita Kataoka, Masashi Takemura, Keiichiroh Okuda, Naoki Mizuno, Hiroyoshi Taketani, Atsushi Umemura,[...]. Diagnostics (Basel) 2020
3

Inflammatory Targets in Diabetic Nephropathy.
Javier Donate-Correa, Desirée Luis-Rodríguez, Ernesto Martín-Núñez, Víctor G Tagua, Carolina Hernández-Carballo, Carla Ferri, Ana Elena Rodríguez-Rodríguez, Carmen Mora-Fernández, Juan F Navarro-González. J Clin Med 2020
30


Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Masashi Tanaka, Hajime Yamakage, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Akira Shimatsu, Noriko Satoh-Asahara. Intern Med 2020
3



The tubular hypothesis of nephron filtration and diabetic kidney disease.
Volker Vallon, Scott C Thomson. Nat Rev Nephrol 2020
49



Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
Christie Rampersad, Eyal Kraut, Reid H Whitlock, Paul Komenda, Vincent Woo, Claudio Rigatto, Navdeep Tangri. Am J Kidney Dis 2020
6

Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
Adrian Post, Dion Groothof, Michele F Eisenga, Stephan J L Bakker. J Clin Med 2020
1

Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.
Sandra Rayego-Mateos, José Luis Morgado-Pascual, Lucas Opazo-Ríos, Melania Guerrero-Hue, Cristina García-Caballero, Cristina Vázquez-Carballo, Sebastián Mas, Ana Belén Sanz, Carmen Herencia, Sergio Mezzano,[...]. Int J Mol Sci 2020
20


Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
Christoph Wanner, Silvio E Inzucchi, Bernard Zinman, Audrey Koitka-Weber, Michaela Mattheus, Jyothis T George, Maximilian von Eynatten, Sibylle J Hauske. Diabetes Obes Metab 2020
5

Practical Strategy for Treating Chronic Kidney Disease (CKD)-Associated with Hypertension.
Daisuke Nagata, Erika Hishida, Takahiro Masuda. Int J Nephrol Renovasc Dis 2020
1

Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
K Melissa Hallow, David W Boulton, Robert C Penland, Gabriel Helmlinger, Emily H Nieves, Daniël H van Raalte, Hiddo L Heerspink, Peter J Greasley. J Pharmacol Exp Ther 2020
1

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.
Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, James L Januzzi, Rita R Kalyani, Mikhail Kosiborod, Melissa Magwire, Pamela B Morris, Joshua J Neumiller,[...]. J Am Coll Cardiol 2020
58

Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db/db mice.
Toru Kusakabe, Shigefumi Yokota, Mika Shimizu, Takayuki Inoue, Masashi Tanaka, Ryuji Ohue-Kitano, Kazuya Muranaka, Hajime Yamakage, Hiromichi Wada, Koji Hasegawa,[...]. BMJ Open Diabetes Res Care 2020
2

A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.
Akira Onishi, Yiling Fu, Rohit Patel, Manjula Darshi, Maria Crespo-Masip, Winnie Huang, Panai Song, Brent Freeman, Young Chul Kim, Manoocher Soleimani,[...]. Am J Physiol Renal Physiol 2020
20